Reports of Radiotherapy and Oncology

Published by: Kowsar

A Survey on the Prevalence of IVS14 + 1G > A Mutation of the Dihydropyrimidine Dehydrogenase Gene Among a Group of Colorectal Cancer Patients in Northeast Iran, the Relevance of Fluoropyrimidine Based Chemotherapy Toxicity

Roham Salek 1 , Bibi Ashraf Hosseini 2 , Javad Behravan 2 , Amir Aledavood 1 and Mahboobeh Sadeghi Ivari 1 , *
Authors Information
1 Cancer Research Center, Mashhad University of Medical Sciences, Mashhad, Iran
2 Biotechnology Research Center, Department of Pharmaceutical Biotechnology, School of Pharmacy, Mashhad University of Medical Sciences, Mashhad, Iran
Article information
  • Reports of Radiotherapy and Oncology: March 2016, 3 (1); e64853
  • Published Online: March 31, 2016
  • Article Type: Research Article
  • Received: January 7, 2016
  • Revised: February 23, 2016
  • Accepted: March 3, 2016
  • DOI: 10.5812/rro.64853

To Cite: Salek R, Hosseini B A, Behravan J, Aledavood A, Sadeghi Ivari M. A Survey on the Prevalence of IVS14 + 1G > A Mutation of the Dihydropyrimidine Dehydrogenase Gene Among a Group of Colorectal Cancer Patients in Northeast Iran, the Relevance of Fluoropyrimidine Based Chemotherapy Toxicity, Rep Radiother Oncol. 2016 ; 3(1):e64853. doi: 10.5812/rro.64853.

Copyright © 2016, Reports of Radiotherapy and Oncology. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License ( which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited
1. Background
2. Methods
3. Results
4. Discussion
  • 1. Jemal A, Center MM, DeSantis C, Ward EM. Global patterns of cancer incidence and mortality rates and trends. Cancer Epidemiol Biomarkers Prev. 2010;19(8):1893-907. doi: 10.1158/1055-9965.EPI-10-0437. [PubMed: 20647400].
  • 2. Islamic Republic of Iran . Ministry of health and medical education: Iranian annual of national cancer registration report. 2004.
  • 3. Potter JD. Colorectal cancer: molecules and populations. J Natl Cancer Inst. 1999;91(11):916-32. doi: 10.1093/jnci/91.11.916. [PubMed: 10359544].
  • 4. Koopman M, Venderbosch S, Nagtegaal ID, van Krieken JH, Punt CJ. A review on the use of molecular markers of cytotoxic therapy for colorectal cancer, what have we learned? Eur J Cancer. 2009;45(11):1935-49. doi: 10.1016/j.ejca.2009.04.023. [PubMed: 19473832].
  • 5. Lu Z, Zhang R, Carpenter JT, Diasio RB. Decreased dihydropyrimidine dehydrogenase activity in a population of patients with breast cancer: implication for 5-fluorouracil-based chemotherapy. Clin Cancer Res. 1998;4(2):325-9. [PubMed: 9516918].
  • 6. Wei X, McLeod HL, McMurrough J, Gonzalez FJ, Fernandez-Salguero P. Molecular basis of the human dihydropyrimidine dehydrogenase deficiency and 5-fluorouracil toxicity. J Clin Invest. 1996;98(3):610-5. doi: 10.1172/JCI118830. [PubMed: 8698850].
  • 7. Sulzyc-Bielicka V, Binczak-Kuleta A, Pioch W, Kladny J, Gziut K, Bielicki D, et al. 5-Fluorouracil toxicity-attributable IVS14 + 1G > A mutation of the dihydropyrimidine dehydrogenase gene in Polish colorectal cancer patients. Pharmacol Rep. 2008;60(2):238-42. [PubMed: 18443386].
  • 8. Tanaka D, Hishida A, Matsuo K, Iwata H, Shinoda M, Yamamura Y, et al. Polymorphism of dihydropyrimidine dehydrogenase (DPYD) Cys29Arg and risk of six malignancies in Japanese. Nagoya J Med Sci. 2005;67(3-4):117-24. [PubMed: 17375478].
  • 9. Suzen HS, Yuce N, Guvenc G, Duydu Y, Erke T. TYMS and DPYD polymorphisms in a Turkish population. Eur J Clin Pharmacol. 2005;61(12):881-5. doi: 10.1007/s00228-005-0054-2. [PubMed: 16328315].
  • 10. Trotti A, Byhardt R, Stetz J, Gwede C, Corn B, Fu K, et al. Common toxicity criteria: version 2.0. an improved reference for grading the acute effects of cancer treatment: impact on radiotherapy. Int J Radiat Oncol Biol Phys. 2000;47(1):13-47. doi: 10.1016/S0360-3016(99)00559-3. [PubMed: 10758303].
  • 11. Raida M, Schwabe W, Hausler P, Van Kuilenburg AB, Van Gennip AH, Behnke D, et al. Prevalence of a common point mutation in the dihydropyrimidine dehydrogenase (DPD) gene within the 5'-splice donor site of intron 14 in patients with severe 5-fluorouracil (5-FU)- related toxicity compared with controls. Clin Cancer Res. 2001;7(9):2832-9. [PubMed: 11555601].
  • 12. Magné N, Renée N, Formento JL, Etienne-Grimaldi MC, Francoual M, Milano G. Prospective study of dihydropyrimidine dehydrogenase (DPD) activity and DPYD IVS14+1G>A mutation in patients developing FU-related toxicities: An updated analysis based on a ten-year recruitment across multiple French institutions. J Clin Oncol. 2005;23(16_suppl):2003. doi: 10.1200/jco.2005.23.16_suppl.2003.
  • 13. van Kuilenburg AB, Muller EW, Haasjes J, Meinsma R, Zoetekouw L, Waterham HR, et al. Lethal outcome of a patient with a complete dihydropyrimidine dehydrogenase (DPD) deficiency after administration of 5-fluorouracil: frequency of the common IVS14+1G>A mutation causing DPD deficiency. Clin Cancer Res. 2001;7(5):1149-53. [PubMed: 11350878].
  • 14. Van Kuilenburg AB, Meinsma R, Zoetekouw L, Van Gennip AH. Increased risk of grade IV neutropenia after administration of 5-fluorouracil due to a dihydropyrimidine dehydrogenase deficiency: high prevalence of the IVS14+1g>a mutation. Int J Cancer. 2002;101(3):253-8. doi: 10.1002/ijc.10599. [PubMed: 12209976].
  • 15. Celik I, Kars A, Guc D, Tekuzman G, Ruacan S. Dihydropyrimidine dehydrogenase enzyme deficiency: clinical and genetic assessment of prevalence in Turkish cancer patients. Cancer Invest. 2002;20(3):333-9. doi: 10.1081/CNV-120001178. [PubMed: 12025228].
  • 16. Hamdy SI, Hiratsuka M, Narahara K, El-Enany M, Moursi N, Ahmed MS, et al. Allele and genotype frequencies of polymorphic cytochromes P450 (CYP2C9, CYP2C19, CYP2E1) and dihydropyrimidine dehydrogenase (DPYD) in the Egyptian population. Br J Clin Pharmacol. 2002;53(6):596-603. [PubMed: 12047484].
  • 17. Hsiao HH, Yang MY, Chang JG, Liu YC, Liu TC, Chang CS, et al. Dihydropyrimidine dehydrogenase pharmacogenetics in the Taiwanese population. Cancer Chemother Pharmacol. 2004;53(5):445-51. doi: 10.1007/s00280-003-0749-y. [PubMed: 15132136].
  • 18. Cho HJ, Park YS, Kang WK, Kim JW, Lee SY. Thymidylate synthase (TYMS) and dihydropyrimidine dehydrogenase (DPYD) polymorphisms in the Korean population for prediction of 5-fluorouracil-associated toxicity. Ther Drug Monit. 2007;29(2):190-6. doi: 10.1097/FTD.0b013e318040b1fe. [PubMed: 17417073].
  • 19. Ahluwalia R, Freimuth R, McLeod HL, Marsh S. Use of pyrosequencing to detect clinically relevant polymorphisms in dihydropyrimidine dehydrogenase. Clin Chem. 2003;49(10):1661-4. doi: 10.1373/49.10.1661. [PubMed: 14500593].

Featured Image:

Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments